Observational studyCornea2017
Late Acute Rejection After Allograft Limbal Stem Cell Transplantation: Evidence for Long-Term Donor Survival.
Observational study in Cornea, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Diagnostic criteria for limbal stem cell deficiency before surgical intervention-A systematic literature review and analysis.Survey of ophthalmologyPooled it
- Clinical practice guideline for aniridia.Japanese journal of ophthalmology · 2026Article
- Research on interdisciplinary measurement and evolutionary path in the field of ophthalmology.Frontiers in ophthalmology · 2025Article
- Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.Lancet (London, England) · 2024Article
- A novel tissue-engineered corneal epithelium based on ultra-thin amniotic membrane and mesenchymal stem cells.Scientific reports · 2024Article
- Mesenchymal Stem Cells and Exosomes: A Novel Therapeutic Approach for Corneal Diseases.International journal of molecular sciences · 2023Review
- A Decellularized Human Limbal Scaffold for Limbal Stem Cell Niche Reconstruction.International journal of molecular sciences · 2021Article
- Genetic Modification of Limbal Stem Cells to Decrease Allogeneic Immune Responses.Frontiers in immunology · 2021Article
- Recent Advances in Stem Cell Therapy for Limbal Stem Cell Deficiency: A Narrative Review.Ophthalmology and therapy · 2020Review
- Cellular therapy of corneal epithelial defect by adipose mesenchymal stem cell-derived epithelial progenitors.Stem cell research & therapy · 2020Article
- Systemic Immunosuppression for Limbal Allograft and Allogenic Limbal Epithelial Cell Transplantation.Medical hypothesis, discovery & innovation ophthalmology journal · 2020Review
- Emerging Approaches for Ocular Surface Regeneration.Current ophthalmology reports · 2019Article
- Concise Review: Stem Cells for Corneal Wound Healing.Stem cells (Dayton, Ohio) · 2017Review
- Limbal and corneal epithelial homeostasis.Current opinion in ophthalmology · 2017Review
- Use of Systemic Mycophenolate Mofetil Therapy in Ocular Surface Inflammatory Pathologies at the Initiative and Responsibility of the Ophthalmologist.Middle East African journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 5 countries.
Funding
Abstract
purposeTo describe the clinical presentation and management of late (>3.0 years) acute graft rejection in keratolimbal allograft (KLAL) recipients.
methodsThis was a multicenter, retrospective observational case series. Six eyes of 6 patients with ocular surface transplant at a mean age of 36.2 years were seen at 3 tertiary referral centers for acute graft rejection between 2007 and 2013. Main outcome measures included strength of systemic immunosuppression (SI) at the time of rejection, time to rejection, and clinical presentation of rejection.
resultsPreoperative diagnoses included total limbal stem cell deficiency because of aniridia (n = 2) or chemical injury (n = 4). After an initially successful outcome, patients experienced late acute graft rejection at a mean time of 67.8 ± 24.1 months (range: 41-98) after KLAL while receiving suboptimal levels of SI because of medication taper (n = 5) or noncompliance (n = 1). Objective findings included an epithelial rejection line (n = 6), edema (n = 2), corneal epithelial irregularities (n = 2), and neovascularization (n = 1). Antirejection management consisted of topical corticosteroids (n = 6) and augmentation of SI therapy (n = 5).
conclusionsThese cases of late acute graft rejection in KLAL patients support the notion that allodonor cells can persist over the long run and remain at risk for immunologic rejection. It further underscores the fact that long-term success with KLAL may require extension of SI beyond the first few years, albeit at lower levels individualized to each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.